The presence of soluble Axl in the serum of patients, for instance, is used as a biomarker for liver cirrhosis and HCC development (108, 109) and receptor tyrosine kinase inhibitors that can inhibit Axl function are currently being tested in therapeutic settings (110). Here, AXL is linked to cirrhosis of liver.